Últimas noticias sobre Duolingo (NASDAQ:DUOL) Bolsa

Duolingo

Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.

Analyst Color

Equities

Large Cap

News

Price Target

Reiteration

Analyst Ratings

Movers

DUOL

Duolingo reporta ingresos mixtos en el 4T. A pesar de resultados débiles en BPA, el analista Ryan MacDonald sube su precio objetivo.

Duolingo (DUOL) ajusta previsiones y recibe incremento en objetivo de precio por analista

Duolingo Inc

<h3>Gainers</h3>
<ul>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock rose 16.3% to $2.35 during Thursday's pre-market session. The company's market cap stands at $3.5 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares moved upwards by 13.68% to $3.49. The company's market cap stands at $8.2 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares rose 11.9% to $0.19. The company's market cap stands at $37.5 million. </li>
<li>WF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WXM#NASDAQ">WXM</a>) stock rose 9.49% to $2.19. The company's market cap stands at $15.1 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) shares increased by 7.43% to $0.26. The market value of their outstanding shares is at $6.6 million. </li>
<li>TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) shares increased by 6.8% to $82.52. The market value of their outstanding shares is at $16.1 billion. As per the press release, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) shares fell 15.8% to $1.07 during Thursday's pre-market session. The company's market cap stands at $8.5 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock declined by 15.68% to $0.22. The company's market cap stands at $21.3 million. </li>
<li>Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) stock fell 13.91% to $39.99. The company's market cap stands at $4.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock fell 10.44% to $0.09. The market value of their outstanding shares is at $12.4 million. </li>
<li>Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) shares decreased by 8.82% to $115.31. The market value of their outstanding shares is at $9.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Primech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) stock decreased by 8.53% to $0.75. The market value of their outstanding shares is at $28.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLE

AREB

GPUS

HTOO

LNZA

PMEC

ZONE

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) shares rose 17.5% to $90.55 during Thursday's pre-market session. The company's market cap stands at $2.5 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) stock increased by 15.98% to $2.54. The company's market cap stands at $44.8 million. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) stock moved upwards by 12.26% to $1.19. The company's market cap stands at $14.1 million. </li>
<li>Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) stock increased by 11.74% to $29.5. The company's market cap stands at $559.9 million. The company's, Q1 earnings came out today. </li>
<li>Materialise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) shares increased by 9.93% to $5.09. The market value of their outstanding shares is at $300.6 million. As per the press release, Q1 earnings came out today. </li>
<li>Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares moved upwards by 9.76% to $5.96. The company's market cap stands at $2.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock fell 14.3% to $0.15 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares decreased by 10.05% to $1.88. The company's market cap stands at $68.6 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares declined by 9.4% to $6.01. The market value of their outstanding shares is at $382.4 million. </li>
<li>Nokia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) stock declined by 8.1% to $4.88. The company's market cap stands at $26.3 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) stock declined by 8.02% to $2.87. The market value of their outstanding shares is at $3.3 million. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares decreased by 7.95% to $3.13. The company's market cap stands at $33.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIXI

BTOG

FARO

MTLS

OBLG

PONY

WETH

ZENA

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

UBER

Uber And Volkswagen To Deploy All-Electric, Fully Autonomous ID Buzz Vehicles

Guidance

ITGR

Integer Holdings Raises FY2025 Adj EPS Guidance from $5.84-$6.20 to $6.15-$6.51 vs $6.06 Est

Stock Split

XFOR

X4 Pharmaceuticals shares are trading lower after the company announced a 1-for-30 reverse stock split.

Biotech

Events

General

RVPH

Reviva To Present Poster On RECOVER Long-Yerm Open Label Extension Trial For Brilaroxazine In Schizophrenia At 2025 ASCP Annual Meeting

X4 Pharmaceuticals Announces 1-for-30 Reverse Stock Split, Which Will Take Effect Apr. 28

<ul>
<li>Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive's nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists.</li>
<li>Northstrive believes the FDA responses encourage a path forward for filing an IND application to conduct a Phase 2 clinical trial in overweight or obese patients.</li>
<li>EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. &nbsp;</li>
</ul>
NEWPORT BEACH, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) (the "Company," "PMGC," "we," or "our"), announced that it has received preliminary responses and commentary from the U.S. Food and Drug Administration ("FDA") regarding its scheduled Type B pre-Investigational New Drug ("pre-IND") meeting. Northstrive initially requested this meeting with the FDA to discuss nonclinical studies and Northstrive Biosciences' clinical development plans for EL-22 administered in combination with GLP-1 receptor agonists. Northstrive believes the FDA's responses support an IND submission for the initiation of a proposed Phase 2 clinical study.

ELAB

Northstrive Biosciences Receives Preliminary Responses And Commentary From FDA Regarding Scheduled Type B Pre-IND Meeting

Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.:
To our valued stockholders,
As we reflect on the Company's progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds.
We currently have two ongoing clinical trials for our lead drug, ENV105, which is being tested in patients with prostate cancer in a Phase 2 trial and is being tested in a Phase 1 trial for patients with a type of lung cancer (called EGFR-dependent non-small cell lung cancer). As part of these trials, we are also identifying and confirming biomarkers to identify patients for whom this combined therapy may prove most effective. Our CSO Dr. Neil Bhowmick's lab received $876,000 from the Department of Defense to support a biomarker study for lung cancer patients responsive to ENV105. In addition to our long-standing, close relationship with Cedars Sinai Hospital in Los Angeles, where we are conducting both trials, we have also expanded the prostate trial sites to the University of Utah and City of Hope. We are aiming to be able to discuss safety and interim efficacy results toward the end of the second quarter 2025.
We are also continuing our development work for our proprietary immune response compounds, including KROS101, designed to treat cancers by increasing the killer T cell population while decreasing the suppressor Treg population. We have reported some exciting data on this GITR ligand small molecule agonist at American Association for Cancer Research meetings, the Society for Immunotherapy of Cancer meeting, and at the upcoming American Society of Clinical Oncology meeting.
There remains significant unmet medical needs in both cancer and inflammation. We believe our research will open new paths to help address these serious conditions. Each of the indications we seek to address represent multi-billion-dollar markets. Further, we continue to receive non-dilutive government grants to support research in several of our programs, even in an environment where these types of grants are in jeopardy of drying up due to the macro political environment. Finally, we have a robust intellectual property portfolio that we believe will provide significant protection into the 2030s.
We now have significant research analyst coverage through several investment banks, including EF Hutton, D. Boral, Rodman and Renshaw, Maxim, and HC Wainwright. Further, we will be participating in the D. Boral Healthcare Conference in May and the HC Wainwright Healthcare Conference in September.
Despite recent economic headwinds, we remain financially strong due to our recent private placement and judicious use of funds with non-dilutive funding. Thank you for your continued support and confidence in our mission. We look forward to providing you with regular updates on our progress as we move forward.
Sincerely,
John Yu, M.D. CEO, Kairos Pharma

KAPA

Kairos Pharma Issues Letter To Stockholders; Updates Two Ongoing Clinical Trials For ENV105 For Patients With Prostate Cancer And KROS101 For Cancer Treatment

First Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRME#NASDAQ">FRME</a>) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.91 by 3.3 percent. This is a 10.59 percent increase over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $160.32 million which missed the analyst consensus estimate of $170.88 million by 6.18 percent. This is a 4.31 percent increase over sales of $153.70 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

FRME

First Merchants Q1 Adj. EPS $0.94 Beats $0.91 Estimate, Sales $160.32M Miss $170.88M Estimate

Carpenter Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) reported quarterly earnings of $1.88 per share which beat the analyst consensus estimate of $1.74 by 8.05 percent. This is a 57.98 percent increase over earnings of $1.19 per share from the same period last year. The company reported quarterly sales of $727.00 million which missed the analyst consensus estimate of $729.87 million by 0.39 percent. This is a 6.15 percent increase over sales of $684.90 million the same period last year.

Carpenter Tech Q3 Adj. EPS $1.88 Beats $1.74 Estimate, Sales $727.00M Miss $729.87M Estimate

Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.25 by 68 percent. This is a 25 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $1.59 billion which missed the analyst consensus estimate of $1.60 billion by 0.31 percent. This is a 46.10 percent decrease over sales of $2.96 billion the same period last year.

TECK

Teck Resources Q1 Adj. EPS $0.42 Beats $0.25 Estimate, Sales $1.59B Miss $1.60B Estimate

Integer Holdings Q1 Adj. EPS $1.31 Beats $1.24 Estimate, Sales $437.00M Beat $428.70M Estimate

WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Shareholder Letter addressing R&amp;D trends for inflammasome inhibitors in development, and provides an update on the development status of Inflammasome ASC Inhibitor IC 100. The full text of the letter follows.
ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with initial focus on Obesity-associated cardiometabolic conditions as the lead. Plans for indication expansion include treatments for Parkinson's and Alzheimer's diseases, and Multiple Sclerosis. The global drug market for anti-inflammatory biologics was valued at $105 billion in 2024, and it's projected to reach $186 billion by 2034 (Precedence Research). This growth is driven by the rising incidence of chronic inflammatory diseases associated with population aging, lifestyle changes, and environmental factors.

ZVSA

ZyVersa Advances IC 100 Inflammasome Inhibitor for Chronic Inflammatory Diseases

Contracts

KOPN

Kopin Announces US army Contract, Size Not Disclosed

AKYA

Akoya Biosciences And Enable Medicine Collaborate To Deliver Single-Cell Spatial Proteomics Atlas

<ul>
<li>Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025</li>
<li>Cocrystal Pharma's pan-viral protease inhibitor CDI-988 shows superior broad-spectrum antiviral activity against major norovirus variants including GII.4 and GII.17 strains</li>
<li>Company reported favorable safety and tolerability of CDI-988 in Phase 1 and plans to initiate a human challenge study in 2025 for the treatment and prevention of norovirus infection &nbsp;<a href="https://www.globenewswire.com/Tracker?data=0PCwPmQ52KsO6N6Tw6N_tSqPT8GBWXsGEqYVIWjW72Tqg02Z6AqsqFEAo7h0jkIzUhwyC7s8UygIdqOX5iLq8rk-e7jqRfgwKfmDrMF-HZw=">Cocrystal Pharma, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) ("Cocrystal" or the "Company") announces that its investigative drug candidate CDI-988 was shown to bind to the highly conserved region of the GII.17 protease with excellent potency, similar to that shown across a range of GII.4 norovirus variants that had been the dominant worldwide strains until this year. The high resolution GII.17 protease crystal structures used in determining CDI-988's activity were obtained using the Company's proprietary structure-based platform technology. Cocrystal plans to initiate a human norovirus challenge study in 2025 in the U.S. to evaluate CDI-988 as a potential prevention and treatment of norovirus infection.</li>
</ul>
"Norovirus is the most common cause of acute gastroenteritis worldwide, yet there are no approved antiviral treatments or vaccines available to combat it," said Sam Lee, Ph.D., Cocrystal's President and co-CEO. "Norovirus antiviral and vaccine development has been extremely challenging due to high diversity among variants that include 10 genogroups and 49 genotypes. We are gratified to have determined the first crystal structure of GII.17 protease and demonstrated broad-spectrum antiviral activity of CDI-988 against newly circulating major norovirus GII.17 variants. Based on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 is a compelling candidate for advancement as a first-in-class oral antiviral to be used for both prevention and treatment of norovirus infection."
"Norovirus is a noteworthy research target considering that each year an <a href="https://www.globenewswire.com/Tracker?data=adeSjx0d2upzrOyfakgMxI9HGo9rTQUw_lm-47ruTdKozM5oBw1loj2uCL5447iF01peOSS4CoXjG3uHSUtkIpyOd0VwdNbCe5S4UATkCjp4v3qhX8VunNltalbHKyGUSCZf9zo8qu54CvOtoOP9Gr61tYVQHENkCyGF2mgAtOy92zadAHfvop1NRIG4iG3iXvZY6PYzO3UgSB8N1PsDdnPgBCy0L4uqhUfZCLlgI4vqkxrIprmmbn_E4DfVtymGcpoAzxWG3o6CpSOYup5W2QFQFyd8tWUc5I9qjEsYQ3IyvriJ4S2XK5VqjZR79uo4uKoYu_8nzGm81hE3fieD9eQQCWHm28dIPTnP-6KPKvHrzMu_h-kyHqqBzHQvEogMIbr_43knpTjN9cM73YVg-29FPOniWPQf4bWkvdsh6MoNcLjRIXNirXTflZ-M1aeNy0rYj_8Zy6KNb-aeKECJ2srqyOS1AfrwsbTs52knvJfBlR3of2Q1G-vgXbBKL6FLCWeSat6-t4jzqrqTTe1SYA0oK_dT97WOGjSqLWRm_0iDdTvsgdRIJqz7VnCCiLyZjszI2mQl68qUtXTtevF85ugDebLDrXealM8Uj1VkJ_0Tz5Rs9Uv1zO8pdvk8eH_fQ81z67_z8szV6UNAq-ldH6_pIqQuoq_h09mlpqzc_o9FVgqkfG0rpnmXXd96OwTxVVeEC0jCDJzGAI03S6DtyfhGqf0dpb-tXLeU1uJZj0sNBCaRZyxaWO29oSB3E3kObWQ6SxXC3ashSn3dOoX-p7WxcJ21eKnCmKAT-ZB6Ovo_szZrz7WYiTMP-rkc0Nq1">estimated 685 million cases and approximately 50,000 child deaths are attributed to this virus worldwide, leading to a societal cost estimated at $60 billion</a>," said James Martin, Cocrystal's CFO and co-CEO. "We are addressing the urgent need for norovirus and other emerging viral outbreaks through our platform technology that facilitates the rapid, efficient development of potentially highly effective and safe direct-acting antivirals."

COCP

Cocrystal Pharma Announces Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against The Emerging GII.17 Variants

In the last three months, 9 analysts have published ratings on Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $603.78, with a high estimate of $750.00 and a low estimate of $450.00. Experiencing a 4.62% decline, the current average is now lower than the previous average price target of $633.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745496100_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Lennox Intl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Betsy Graseck &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $450.00&#x7C;$585.00 &#x7C; 
&#x7C;Stephen Tusa &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $455.00&#x7C;$565.00 &#x7C; 
&#x7C;Tommy Moll &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $750.00&#x7C;$750.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $702.00&#x7C;$665.00 &#x7C; 
&#x7C;Joseph O'Dea &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $580.00&#x7C;$630.00 &#x7C; 
&#x7C;Brett Linzey &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $625.00&#x7C;$675.00 &#x7C; 
&#x7C;Deane Dray &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $642.00&#x7C;$617.00 &#x7C; 
&#x7C;Stephen Tusa &#x7C;JP Morgan &#x7C;Raises &#x7C;Underweight &#x7C; $565.00&#x7C;$536.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $665.00&#x7C;$674.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lennox Intl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Lennox Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Lennox Intl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LII/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lennox Intl analyst ratings.</a>
<h2>About Lennox Intl</h2>
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
<h3>Lennox Intl's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Lennox Intl's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.47% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lennox Intl's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Lennox Intl's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 24.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Lennox Intl's ROA stands out, surpassing industry averages. With an impressive ROA of 5.83%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Lennox Intl's debt-to-equity ratio stands notably higher than the industry average, reaching 1.75. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Lennox Intl: 9 Analysts Share Their Views

Akoya Biosciences Expands Portfolio With ADC Breast Cancer Assay And Real-world IO60 Insights At AACR 2025

10 analysts have shared their evaluations of First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $23.8, a high estimate of $28.00, and a low estimate of $21.00. This current average reflects an increase of 0.42% from the previous average price target of $23.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1745496074_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of First Watch Restaurant Gr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Salera &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $24.00&#x7C;$24.00 &#x7C; 
&#x7C;Dan Levy &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $24.00&#x7C;$21.00 &#x7C; 
&#x7C;Andrew Charles &#x7C;TD Securities &#x7C;Raises &#x7C;Buy &#x7C; $22.00&#x7C;$21.00 &#x7C; 
&#x7C;Jim Salera &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $24.00&#x7C;$24.00 &#x7C; 
&#x7C;Dan Levy &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $21.00&#x7C;$24.00 &#x7C; 
&#x7C;Jim Salera &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Overweight &#x7C; $24.00&#x7C;$25.00 &#x7C; 
&#x7C;Sara Senatore &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $28.00&#x7C;$27.00 &#x7C; 
&#x7C;Andrew Charles &#x7C;TD Securities &#x7C;Maintains &#x7C;Hold &#x7C; $21.00&#x7C;$21.00 &#x7C; 
&#x7C;Jim Salera &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $25.00&#x7C;$25.00 &#x7C; 
&#x7C;Jim Salera &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $25.00&#x7C;$25.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to First Watch Restaurant Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Watch Restaurant Gr compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for First Watch Restaurant Gr's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of First Watch Restaurant Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FWRG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Watch Restaurant Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About First Watch Restaurant Gr</h2>
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
<h3>Unraveling the Financial Story of First Watch Restaurant Gr</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: First Watch Restaurant Gr's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.63%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: First Watch Restaurant Gr's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.12%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: First Watch Restaurant Gr's debt-to-equity ratio is below the industry average at 1.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FWRG

Forecasting The Future: 10 Analyst Projections For First Watch Restaurant Gr

Education

Press Releases

Duolingo Introduces AI-Powered Innovations at Duocon 2024

Duolingo to Announce Third Quarter 2024 Results on Wednesday, November 6, 2024

Management

Gaming Industry Visionary Bonnie Ross Joins Duolingo Board of Directors

Duolingo and Netflix Partner Launch 'Learn Korean or Else' Campaign Ahead of Squid Game Season 2

Duolingo Launches AI-Powered Video Call for Android

Duolingo to Announce Fourth Quarter and Full Year 2024 Results on Thursday, February 27, 2025

Duolingo to Participate in Upcoming Investor Conferences

Duolingo Finishes 2024 with 51% DAUs growth, more than 40 Million DAUs, and Record Revenue in the Fourth Quarter

Duolingo Announces the Grand Opening of Duo's Treehouse

Duolingo to Announce First Quarter 2025 Results on Thursday, May 1, 2025

Afya

American Public Education, Inc. - Common Stock

American Public Education

Adtalem Global Education Inc. Common Stock

Adtalem Glb Education

Bright Horizons Family Solutions Inc. Common Stock

Bright Horizons Family

China Liberal Education Holdings Limited - Ordinary Shares

China Liberal Education

Coursera

Youdao, Inc. American Depositary Shares, each representing one Class A Ordinary Share

Youdao

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 10 Ordinary Share (Cayman Islands)

New Oriental Education

Graham Hldgs

Gaotu Techedu Inc. American Depositary Shares

Gaotu Techedu

KinderCare Learning Companies, Inc. Common Stock

KinderCare Learning

Laureate Education

Lincoln Educational Services Corporation - Common Stock

Lincoln Educational Servs

Grand Canyon Education, Inc. - Common Stock

Grand Canyon Education

Stride

Jinxin Technology Holding Company - American Depositary Shares

Jinxin Technology Holding

Perdoceo Education Corporation - Common Stock

Perdoceo Education

Pearson

QuantaSing Group Limited - American Depositary Shares

QuantaSing Group

Ruanyun Edai Technology Inc. - Ordinary shares

Ruanyun Edai Technology

Strategic Education

TAL Education Group American Depositary Shares

TAL Education

Udemy

Universal Technical Institute Inc Common Stock

Universal Technical

Vasta Platform Limited - Class A Ordinary Shares

Comments

Duolingo

Noticias

Últimas noticias sobre Duolingo (NASDAQ:DUOL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL